resiquimod has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benoit, B; Buchanan, MA; Clark, RA; Elenitsas, R; Gelfand, JC; Gelfand, JM; Kim, EJ; Kirsch, IR; Leahy, DS; Rook, AH; Surber, C; Troxel, AB; Watanabe, R; Wysocka, M | 1 |
1 trial(s) available for resiquimod and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Female; Humans; Imidazoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin; Skin Neoplasms; T-Lymphocytes | 2015 |